PSA-RP2 is a variant transcript expressed from the PSA gene that is conserved in gorillas, chimpanzees and humans suggesting a particular relevance for this transcript in these primates. We demonstrated by qRT-PCR that PSA-RP2 is upregulated in prostate cancer compared with benign prostatic hyperplasia tissues. The PSA-RP2 protein was not detected in seminal fluid and was cytoplasmically localised but not secreted from LNCaP or transfected PC3 prostate cells, despite secretion from transfected Cos-7 and HEK293 kidney cell lines. PSA-RP2-transfected PC3 cells showed slightly decreased proliferation and increased migration towards PC3-conditioned medium that could suggest a functional role in prostate cancer.
kallikrein-related peptidase (KLK) family of serine proteases consists of 15 genes, each of which produces more than one mRNA transcript (Clements et al., 2004; Kurlender et al., 2005; Tan et al., 2006) . Over 80 mRNA transcripts arise from the kallikrein-related peptidase family (Kurlender et al., 2005) , but on the whole the variant transcripts have been poorly characterised and their roles within the cell are largely unknown. Across the KLK gene family, exon skipping is the most common event that gives rise to alternative transcripts (Kurlender et al., 2005) . Intron retention is also a frequent event, and usually involves the retention of intron 3 (Kurlender et al., 2005) with only two reported cases of intron 1 retention (David et al., 2002) . In the case of the PSA (KLK3) gene, analysis of the sequences surrounding intron 3 suggested suboptimal splice sites (Heuze-Vourc'h et al., 2003) . The vast majority of variant KLK transcripts encode truncated proteins (Kurlender et al., 2005) , and as most of these lack one or more residues of the catalytic triad they are not expected to possess serine protease activity (Tan et al., 2006 ). This does not preclude novel non-proteolytic roles for these variant KLK proteins, as previously described for PSA in stimulating the release of reactive oxygen species (Sun et al., 2001 ) and anti-angiogenesis (Fortier et al., 2003) .
Prostate-specific antigen (PSA or KLK3) is the biomarker used in diagnosis and monitoring of prostate cancer. It is secreted by prostate epithelial cells into the prostate gland and subsequently into seminal fluid where it plays a major role in the degradation of semenogelin (Lundwall and Brattsand, 2008) . Although an excellent marker for tumour recurrence, the PSA blood test lacks specificity and, furthermore, in prostate cancer, does not discriminate aggressive cancers from more slow-growing disease; therefore, improved diagnostic and prognostic markers are needed (Steuber et al., 2008; Stephan et al., 2009) . Several variant transcripts from the PSA gene have been identified, including two transcripts, PSA-RP2 and PSA-424 (Riegman et al., 1988; HeuzeVourc'h et al., 2001) , which arise owing to retention of intron 3 and differ only by the length of their 39UTR. The fulllength PSA protein is 261 residues in length. The protein expressed from both the PSA-RP2 and PSA-424 transcripts is 180 residues in length ( Figure 1A) , in which the first 164 residues are identical to PSA, followed by a unique 16 residue sequence before a premature stop codon (GenBank ࠻CAC41631; Figure 1B) . Expression of the PSA-RP2 protein has been confirmed previously in prostatic tissue (Heuze-Vourc'h et al., 2001 . As PSA-RP2 lacks the serine residue of the catalytic triad ( Figure 1A) , it is not Residues 165-180 of the PSA-RP2 protein (bold underline) are derived from the retained intron 3 sequence and are unique to PSA-RP2. (C) PSA-RP2 mRNA expression is higher in prostate cancer than BPH. Total RNA was extracted using Tri-Reagent (SigmaAldrich, Castle Hill, NSW, Australia) from prostate tissues from men with prostate cancer or BPH who gave informed consent following the approval of the relevant institutional human ethics committees. RNA was treated with DNase I (Roche Applied Science, Castle Hill, NSW, Australia) before reverse transcription using Superscript II (Invitrogen, Mulgrave, VIC, Australia) and an oligo-dT primer. Real-time RT-PCR was performed using SYBR Green I (Applied Biosystems, Victoria, Australia) and primers for PSA-RP2 (forward: 59-GAG TGT ACG CCT GGG CCA GAT-39; reverse: 59-CTG AGG GTG AAC TTG CGC ACA C-39). Relative levels of gene expression were normalised to b2-microglobulin. Each sample was amplified twice in duplicate. Statistical analysis was performed with the Student t-test. Data is shown as average "standard error and demonstrates that PSA-RP2 mRNA expression is significantly higher in prostate cancer (19 patients) compared with BPH (14 patients) (p-0.05). (D) PSA-RP2 is not secreted into seminal fluid. Western blot analysis of LNCaP prostate cancer cell lysate (dihydrotestosterone-treated) and seminal fluid (10 ml -PSA Western; 20 ml -PSA-RP2 Western) run on a 12% SDS-PAGE under reducing conditions. The polyclonal PSA antibody was from Dako Australia (Campbellfield, VIC, Australia). The polyclonal antibody to PSA-RP2 was raised in rabbits (IMVS, Adelaide, Australia) against a synthetic peptide (CTPGPDGAAGSPDAWV) corresponding to the unique C-terminal 16 residues of PSA-RP2 ( Figure 1A ) conjugated to keyhole limpet hemocyanin (Mimotopes, Melbourne, Australia). The antiserum was affinity-purified using the immunising peptide conjugated to thiopropyl sepharose (Mimotopes). Despite high levels of PSA, no PSA-RP2 was detected in the seminal fluid sample.
expected to retain any of the catalytic activities of PSA; however, this would not preclude a potential non-proteolytic function and/or its possible utility as a biomarker.
The use of additional biomarkers and other parameters, combined with serum PSA in multivariate models, could increase the specificity of prostate cancer detection and reduce unnecessary biopsies (Sardana et al., 2008; Stephan et al., 2009 ). For example, %free PSA has been reported to decrease the false positive rate by helping to distinguish the contribution to total PSA from non-cancerous prostatic conditions such as benign prostatic hyperplasia (BPH) (Stenman et al., 1999 ) and other PSA transcriptionally regulated (pro-PSA) and post-translationally generated variants (B-PSA) have been mooted as potentially useful adjunct biomarkers (Linton et al., 2003; Khan et al., 2004; Mikolajczyk et al., 2004) .
To determine its potential relevance to prostate cancer, we first assessed PSA-RP2 gene expression in patient tissues. RNA obtained from prostate cancer (19 patients) and BPH (14 patients) tissues was analysed by quantitative real-time PCR for levels of PSA-RP2 expression. This demonstrated that PSA-RP2 mRNA was significantly overexpressed in prostate cancer versus BPH (p-0.05; Figure 1C ). No significant correlation of PSA-RP2 expression with tumour grade was found in this small cohort (data not shown). We performed further characterisation of this protein to determine its role in prostate cancer cells and as a possible biomarker for prostate cancer. A specific rabbit polyclonal PSA-RP2 antibody was raised against a synthetic peptide corresponding to the 16-residue C-terminal sequence unique to PSA-RP2 (CTPGPDGAAGSPDAWV) ( Figure 1B ). Although this antibody could detect PSA-RP2 in LNCaP prostate cancer cell lysates, no secretion of PSA-RP2 into seminal fluid could be detected, despite high levels of PSA ( Figure 1D ). This was unexpected as PSA-RP2 retains the N-terminal signal peptide required for secretion of PSA. In addition, previous results (Heuze-Vourc'h et al., 2001 ) had demonstrated secretion of recombinant PSA-RP2 from Cos-7 cells. To resolve this, we transfected PSA-RP2 into a range of cell lines and showed that it was localised to the cytoplasm as would be expected for a secreted protein (Figure 2A ). We also confirmed that it was secreted from Cos-7 cells and an additional kidney cell line (HEK293) but not from two prostatic cell lines (endogenous LNCaP, transfected PC3; Figure 2B ). Glycosylation of PSA-RP2 (results not shown) leads to an increased molecular mass which probably accounts for the size difference between the secreted and intracellular forms in Cos-7 and HEK293 cells. In prostate cancer tissue sections ( Figure 2C ), some cancerous glands stained more strongly than non-cancerous, benign-appearing regions of the same tissue. Overall, however, on scoring of the staining across four sections no consistent difference in PSA-RP2 intensity was apparent between benign and cancerous regions. In addition, some PSA-RP2 protein appeared to be localised in the nucleus, as has been reported for KLK4 (Dong et al., 2005) .
From these findings it appears that PSA-RP2 is neither secreted by cultured prostatic cells nor into seminal fluid, although further studies would be necessary to investigate PSA-RP2 levels further in seminal fluid samples and in serum. Although PSA-RP2 is identical to PSA at the N-terminus, and therefore contains the signal peptide required for secretion, the C-terminus is truncated which could alter the folding of the protein and impede its secretion. The fact that the protein is secreted from neither LNCaP nor PC3 cells most probably reflects differences in secretory organelles and efficiencies, perhaps related to glycosylation events, between renal and prostatic cells. Unless there is significant basal leakage into serum, it is unlikely that PSA-RP2 would be found in the circulation, and thus the likelihood that it could be used as a serum biomarker is limited. Nevertheless, it could still serve as a useful discriminator for immunohistochemical screening of biopsy samples, although confirmatory studies would be required to evaluate this potential application.
Although it appears that PSA-RP2 is unlikely to have utility as a secreted biomarker, we also aimed to address whether the upregulation of PSA-RP2 in prostate cancer could play a role in initiation or progression of prostate cancer. To this end, we expressed PSA-RP2 in PC3 prostate cancer cells and performed proliferation and migration assays. PSA-RP2 was not expected to be a catalytically active serine protease, owing to truncation of the protein before the serine residue of the catalytic triad. However, functions for PSA that are unrelated to its catalytic activity have been reported previously (Sun et al., 2001; Fortier et al., 2003) and the large number of variant transcripts (over 80 identified transcripts; Kurlender et al., 2005; Tan et al., 2006) identified for the family of kallikrein-related peptidases raises questions about their roles within cells. As PC3 cells lack expression of PSA-RP2, we used this cell line to study the effects of PSA-RP2 expression in prostatic cells. PC3 cells were transfected with a construct encoding PSA-RP2, or vector only, and stably transfected clones were selected. Three vector-control clones and three PSA-RP2-expressing clones with varying expression levels were selected for further study ( Figure 3A) . Overall, PSA-RP2-expressing clones had slightly decreased proliferation rates at the 72-h time point ( Figure 3B ). Proliferation rates of the individual PSA-RP2-expressing clones are negatively correlated with levels of PSA-RP2 expression (data not shown). As we have previously demonstrated increased migration in PC3 cells expressing PSA (VeverisLowe et al., 2005) , we also investigated migration of PSA-RP2-expressing PC3 cells across microporous membranes. Unlike PSA, PSA-RP2 does not appear to affect migration towards 20% foetal calf serum (FCS; Figure 3C ). We additionally investigated migration towards PC3 conditioned medium ( Figure 3D ) with the rationale that we had previously shown that PC3 cells can secrete chemoattractants that induce other KLK-transfected (KLK4) PC3 cells to increase migration (Gao et al., 2007) . A statistically significant increase in migration (p-0.01) was seen in one PSA-RP2 expressing clone (࠻5H) compared with vector-transfected PC3 cells; however, no significant difference was seen for PSA-RP2-expressing clone ࠻10D, which expressed the highest amounts of PSA-RP2.
Although our study demonstrated limited changes to functional parameters following PSA-RP2 expression, this does not preclude the possibility that other functional effects of PSA-RP2 or other kallikrein variants could arise through non-catalytic interactions with active kallikrein-related peptidases, their inhibitors or other cellular proteins or through interference by the variant mRNAs at a transcriptional level. Further research is required to investigate these parameters. However, it is interesting to note that sequences with very high sequence identity to PSA-RP2 (98% protein identity) exist in gorillas and chimpanzees (Dorus et al., 2004 ; GenBank numbers AAV51952, AAV51953), raising the possibility of conservation of this transcript and further suggesting a func- (A) Confocal microscopy demonstrates cytoplasmic localisation of PSA-RP2 in transfected LNCaP cells. PSA-RP2 was amplified by PCR from prostate cancer tissue cDNA (forward primer, 59-ATC GAA TTC GCA CCC GGA GAG CTG TGT-39; reverse primer, 59-GAA CTC GAG TCA GAC CCA GGC ATC TGG-39) and cloned into pcDNA3.1/V5-His/A (Invitrogen). LNCaP cells seeded onto coverslips were transfected with the above construct using Lipofectamine 2000. Two days post-transfection, cells were fixed with 4% paraformaldehyde, blocked with 2% bovine serum albumin (BSA) in phosphate-buffered saline with 0.01% saponin for 30 min and then incubated overnight with anti-V5 primary antibody (Invitrogen, 1:500 dilution) at 48C. Following incubation with a goat anti-mouse IgG AlexaFluor-488 secondary antibody together with phalloidin-568 nm (Molecular Probes, Eugene, OR, USA), coverslips were mounted using Prolong Gold antifade mounting media (Molecular Probes). Cells were imaged using a Leica confocal microscope. (B) PSA-RP2 is secreted from cultured kidney cells but not prostate cells. For androgen treatment, LNCaP cells were cultured in 2% charcoal-stripped FCS for 72 h and then treated with 1 nM R1881 (dissolved in ethanol) or 0.1% ethanol control for a further 48 h. A similar pcDNA3.1 construct to that above encoding untagged PSA-RP2 was transiently transfected into Cos-7 and HEK-293 cells and stably transfected into PC3 cells. b-Tubulin antibody (TUB2.1, Sigma) was used as a cytoplasmic and loading control for Western blot analysis. Equivalent amounts of conditioned medium (CM) were loaded for each sample (equal to 180 ml of original medium). Loading of whole cell lysates (WCLs) was 50 mg for PC3/PSA-RP2 and 15 mg for other lysates. (C) Immunohistochemical analysis of PSA-RP2 expression in prostate tissues. Four archival formalin-fixed paraffin-embedded blocks from primary prostate cancers (Gleason scores 3q4 to 4q5) were used following institutional ethics approval. Immunohistochemistry was performed as previously described (Dong et al., 2005) using PSA-RP2 polyclonal rabbit antibody (1:100 dilution). The EnVision peroxidase polymer detection system (Dako, Botany, Australia) was used for detection and the sections were counterstained with Mayer's haematoxylin and staining scored by a pathologist (H.M.S.). Panel (a), more intense PSA-RP2 staining was seen in the cancerous (PCa) than benign ( tional importance. Increasingly, the kallikrein-related peptidases are being associated with incidence or progression of a number of cancers (Borgono and Diamandis 2004; Clements et al., 2004) . Thus, given the potential of other PSA-related variant forms (Linton et al., 2003; Khan et al., 2004; Mikolajczyk et al., 2004) , a comprehensive analysis of the functionality and biomarker potential of all KLK variants is warranted. Even if such a venture did not identify novel and useful diagnostic or prognostic markers, it could reveal important activities involving other genes and gene products, thus leading to a better understanding of the function of the high levels of these enzymes in prostate cancer cells and, as a consequence, identify targets for future therapeutic strategies. 5 cells in serum-free, phenol red-free RPMI 1640 medium containing 0.1% BSA, and allowed to migrate towards 20% FCS as chemoattractant in the lower chamber for 24 h. Non-migrated cells remaining in the upper chamber were removed with a cotton swab and then cells that had migrated to the underside of the chamber were fixed with cold methanol. To quantify the number of migrated cells, cells were stained using 1% crystal violet/20% methanol, washed and dried. The remaining stain was solubilised with 10% acetic acid and read in duplicate in a microplate reader at 595 nm. Results shown are the average of three independent experiments, each performed in triplicate, corrected for 24-h proliferation and showing average absorbance "standard error. (D) PSA-RP2 expression could increase the migration of PC3 cells towards PC3 conditioned medium. Migration assays were performed as above (panel C), except that PC3-conditioned medium was used as chemoattractant. Results shown are the average of three independent experiments, each performed in triplicate, showing average absorbance "standard error.
